Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells
Type 1 diabetes is an autoimmune disease resulting in the permanent destruction of pancreatic islets. Islet transplantation to portal vein provides an approach to compensate for loss of insulin producing cells. Clinical trials demonstrated that even partial islet graft function reduces severe hypogl...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2016/3764681 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565617560911872 |
|---|---|
| author | Nadine E. Rekittke Meidjie Ang Divya Rawat Rahul Khatri Thomas Linn |
| author_facet | Nadine E. Rekittke Meidjie Ang Divya Rawat Rahul Khatri Thomas Linn |
| author_sort | Nadine E. Rekittke |
| collection | DOAJ |
| description | Type 1 diabetes is an autoimmune disease resulting in the permanent destruction of pancreatic islets. Islet transplantation to portal vein provides an approach to compensate for loss of insulin producing cells. Clinical trials demonstrated that even partial islet graft function reduces severe hypoglycemic events in patients. However, therapeutic impact is restrained due to shortage of pancreas organ donors and instant inflammation occurring in the hepatic environment of the graft. We summarize on what is known about regenerative therapy in type 1 diabetes focusing on pancreatic islet transplantation and new avenues of cell substitution. Metabolic pathways and energy production of transplanted cells are required to be balanced and protection from inflammation in their intravascular bed is desired. Mesenchymal stem cells (MSCs) have anti-inflammatory features, and so they are interesting as a therapy for type 1 diabetes. Recently, they were reported to reduce hyperglycemia in diabetic rodents, and they were even discussed as being turned into endodermal or pancreatic progenitor cells. MSCs are recognized to meet the demand of an individual therapy not raising the concerns of embryonic or induced pluripotent stem cells for therapy. |
| format | Article |
| id | doaj-art-ea2fa446f0db48bf8482c3fb3ce5f5bf |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-ea2fa446f0db48bf8482c3fb3ce5f5bf2025-02-03T01:07:20ZengWileyStem Cells International1687-966X1687-96782016-01-01201610.1155/2016/37646813764681Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem CellsNadine E. Rekittke0Meidjie Ang1Divya Rawat2Rahul Khatri3Thomas Linn4Clinical Research Unit, Zentrum für Innere Medizin, Fachbereich Medizin, Justus Liebig Universität Giessen, 35392 Giessen, GermanyClinical Research Unit, Zentrum für Innere Medizin, Fachbereich Medizin, Justus Liebig Universität Giessen, 35392 Giessen, GermanyClinical Research Unit, Zentrum für Innere Medizin, Fachbereich Medizin, Justus Liebig Universität Giessen, 35392 Giessen, GermanyClinical Research Unit, Zentrum für Innere Medizin, Fachbereich Medizin, Justus Liebig Universität Giessen, 35392 Giessen, GermanyClinical Research Unit, Zentrum für Innere Medizin, Fachbereich Medizin, Justus Liebig Universität Giessen, 35392 Giessen, GermanyType 1 diabetes is an autoimmune disease resulting in the permanent destruction of pancreatic islets. Islet transplantation to portal vein provides an approach to compensate for loss of insulin producing cells. Clinical trials demonstrated that even partial islet graft function reduces severe hypoglycemic events in patients. However, therapeutic impact is restrained due to shortage of pancreas organ donors and instant inflammation occurring in the hepatic environment of the graft. We summarize on what is known about regenerative therapy in type 1 diabetes focusing on pancreatic islet transplantation and new avenues of cell substitution. Metabolic pathways and energy production of transplanted cells are required to be balanced and protection from inflammation in their intravascular bed is desired. Mesenchymal stem cells (MSCs) have anti-inflammatory features, and so they are interesting as a therapy for type 1 diabetes. Recently, they were reported to reduce hyperglycemia in diabetic rodents, and they were even discussed as being turned into endodermal or pancreatic progenitor cells. MSCs are recognized to meet the demand of an individual therapy not raising the concerns of embryonic or induced pluripotent stem cells for therapy.http://dx.doi.org/10.1155/2016/3764681 |
| spellingShingle | Nadine E. Rekittke Meidjie Ang Divya Rawat Rahul Khatri Thomas Linn Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells Stem Cells International |
| title | Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells |
| title_full | Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells |
| title_fullStr | Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells |
| title_full_unstemmed | Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells |
| title_short | Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells |
| title_sort | regenerative therapy of type 1 diabetes mellitus from pancreatic islet transplantation to mesenchymal stem cells |
| url | http://dx.doi.org/10.1155/2016/3764681 |
| work_keys_str_mv | AT nadineerekittke regenerativetherapyoftype1diabetesmellitusfrompancreaticislettransplantationtomesenchymalstemcells AT meidjieang regenerativetherapyoftype1diabetesmellitusfrompancreaticislettransplantationtomesenchymalstemcells AT divyarawat regenerativetherapyoftype1diabetesmellitusfrompancreaticislettransplantationtomesenchymalstemcells AT rahulkhatri regenerativetherapyoftype1diabetesmellitusfrompancreaticislettransplantationtomesenchymalstemcells AT thomaslinn regenerativetherapyoftype1diabetesmellitusfrompancreaticislettransplantationtomesenchymalstemcells |